A recent study suggests that people who discontinue new GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who end conventional diet and exercise programs.
Findings released in a leading health publication demonstrates that while obese people often shed substantial amounts of their total mass while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month upon discontinuation.
"Individuals buying such medications must be informed of the potential of rapid weight regain when the therapy is stopped," stated lead investigator Dr. Susan Jebb.
This pace of regain implies a reversion to pre-treatment mass in about 18 months.
Comparing Therapies
The study, which examined dozens of trials involving over 9,000 of participants, compared the results of GLP-1 agonists with other pills.
Researchers point out that people who lose weight through diet and exercise usually experience a less rapid creep back—around 0.1 kg a month—after stopping.
Explaining the Quick Regain
Experts believe the mode of action of the jabs is key to understanding the amplified rebound.
The injections mimic a body's own chemical called GLP-1, which helps regulate hunger.
"Long-term administration of GLP-1 concentrations far above than normal might result in the body to produce less of its own natural hormone, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this GLP-1 'fix' results in hunger is no longer kept in check, making excessive eating a significant risk."
A Lifelong Disease?
Medical guidelines advise the injections for individuals with weight-linked medical conditions, alongside recommended lifestyle changes.
Many experts say that, given the significant potential of weight regain, the treatment is often long-term.
This opinion is echoed by drug manufacturers, who note that the results "highlight the persistent nature of excess weight," similar to managing conditions like hypertension.
User Experiences
Users who have discontinued the jabs describe a intense resurgence of appetite.
"It was like a trigger that goes on and you're instantly extremely hungry," said one woman.
The struggle is compounded if users have not developed lasting dietary or behavioural changes during treatment.
Significant Adoption
Survey data show that millions of people in the UK have used these injections in the last 12 months, with interest remaining high.
- Adoption is greater among women than males.
- The middle-aged demographic shows the highest level of interest.
- A large proportion obtain the medications through private healthcare rather than public health services.
Ultimately, experts emphasize that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone cure and long-term success hinges on combined behavioural management.
